Elliott C Dasenbrook1, Michael W Konstan2, Donald R VanDevanter3. 1. Case Western Reserve University School of Medicine, Cleveland, OH, United States; Rainbow Babies and Children's Hospital, Cleveland, OH, United States. Electronic address: elliott.dasenbrook@case.edu. 2. Case Western Reserve University School of Medicine, Cleveland, OH, United States; Rainbow Babies and Children's Hospital, Cleveland, OH, United States. Electronic address: michael.konstan@case.edu. 3. Case Western Reserve University School of Medicine, Cleveland, OH, United States; Rainbow Babies and Children's Hospital, Cleveland, OH, United States. Electronic address: drv15@case.edu.
Abstract
BACKGROUND: In 2010, aztreonam for inhalation solution joined aminoglycosides and colistimethate as a new cystic fibrosis (CF) chronic inhaled antimicrobial therapy. We studied how the introduction of this new inhaled antibiotic class changed the management of US CF patients. METHODS: The use of inhaled aminoglycosides, colistimethate, and aztreonam among patients followed in the CF Foundation Patient Registry was analyzed by age group, lung disease stage, and microbiologic status both annually, and at individual visits between 2009 and 2012. RESULTS: The overall prevalence of inhaled antibiotic use did not change during the period, but the prevalence of annual and any visit treatment with >1 inhaled antibiotic class more than doubled. Adults, those with advanced lung disease, and those with >1 Pseudomonas aeruginosa respiratory culture were more likely to receive >1 antibiotic class. CONCLUSIONS: Inhaled antibiotic management of US CF patients has dramatically changed in association with the introduction of a third inhaled antibiotic class.
BACKGROUND: In 2010, aztreonam for inhalation solution joined aminoglycosides and colistimethate as a new cystic fibrosis (CF) chronic inhaled antimicrobial therapy. We studied how the introduction of this new inhaled antibiotic class changed the management of US CFpatients. METHODS: The use of inhaled aminoglycosides, colistimethate, and aztreonam among patients followed in the CF Foundation Patient Registry was analyzed by age group, lung disease stage, and microbiologic status both annually, and at individual visits between 2009 and 2012. RESULTS: The overall prevalence of inhaled antibiotic use did not change during the period, but the prevalence of annual and any visit treatment with >1 inhaled antibiotic class more than doubled. Adults, those with advanced lung disease, and those with >1 Pseudomonas aeruginosa respiratory culture were more likely to receive >1 antibiotic class. CONCLUSIONS: Inhaled antibiotic management of US CFpatients has dramatically changed in association with the introduction of a third inhaled antibiotic class.
Authors: Peter J Mogayzel; Edward T Naureckas; Karen A Robinson; Gary Mueller; Denis Hadjiliadis; Jeffrey B Hoag; Lisa Lubsch; Leslie Hazle; Kathy Sabadosa; Bruce Marshall Journal: Am J Respir Crit Care Med Date: 2013-04-01 Impact factor: 21.405
Authors: Samuel M Moskowitz; Stefanie J Silva; Nicole Mayer-Hamblett; David J Pasta; David R Mink; Jenny A Mabie; Michael W Konstan; Jeffrey S Wagener Journal: Pediatr Pulmonol Date: 2008-09
Authors: Dave P Nichols; Anthony G Durmowicz; Ann Field; Patrick A Flume; Donald R VanDevanter; Nicole Mayer-Hamblett Journal: Ann Am Thorac Soc Date: 2019-05
Authors: Giovanni Taccetti; Michela Francalanci; Giovanna Pizzamiglio; Barbara Messore; Vincenzo Carnovale; Giuseppe Cimino; Marco Cipolli Journal: Antibiotics (Basel) Date: 2021-03-22